Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Glucagon

November 15, 2018

Zealand Q3 '18 Earnings; Xeris Initiates New Ph3 Study vs. GlucaGen

Here is a brief preview of this blast: Zealand hosted its Q3 '18 earnings call and provided updates to its dasiglucagon development program. Additionally, a new Ph3 Xeris glucagon study vs. Novo's GlucaGen has been observed. Of note, Zealand narrowed its filing timeline for dasiglucagon hypoglycemia from H2 '19 to Q4 '19. Below, FENIX provides thoughts on the dasiglucagon hypoglycemia rescue program, Zealand's ongoing partnership discussions for dasiglucagon commercialization, and Xeris's new Ph3 study.